Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar;35(2):517-525.
doi: 10.1007/s40620-021-01104-z. Epub 2021 Jun 26.

Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial

Luigi Morrone  1 , Suetonia C Palmer  2 , Valeria M Saglimbene  3 , Annalisa Perna  4 , Giuseppe Cianciolo  5 , Domenico Russo  6 , Loreto Gesualdo  7 , Patrizia Natale  3   7 , Antonio Santoro  8 , Sandro Mazzaferro  9 , Mario Cozzolino  10 , Adamasco Cupisti  11 , Marina Di Luca  12 , Biagio Di Iorio  13 , Giovanni F M Strippoli  14   15 ; Mineral Metabolism Study Group of the Italian Society of Nephrology
Collaborators, Affiliations
Randomized Controlled Trial

Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial

Luigi Morrone et al. J Nephrol. 2022 Mar.

Abstract

Background: Vitamin D deficiency is associated with increased risks of mortality in people with chronic kidney disease. The benefits and harm of vitamin D supplementation on cardiovascular outcomes and mortality are unknown. We aimed to assess the effectiveness of calcifediol in reducing mortality in patients with vitamin D insufficiency on hemodialysis compared to no additional therapy.

Methods: A phase III, multicenter, randomized, open-label trial was conducted including 284 adults with vitamin D insufficiency undergoing hemodialysis who were randomly assigned to receive oral calcifediol or standard care for 24 months.

Results: Two hundred eighty-four participants were enrolled (143 assigned to the calcifediol group and 141 to the no additional therapy group). The primary outcome (mortality) occurred in 34 and 31 participants in the calcifediol and control group, respectively [hazard ratio (HR) 1.03; 95% confidence interval (CI) 0.63-1.67]. Calcifediol had no detectable effects on cardiovascular death (HR 1.06; 95% CI 0.41-2.74), non-cardiovascular death (HR 1.13; 95% CI 0.62-2.04), nonfatal myocardial infarction (HR 0.20; 95% CI 0.02-1.67) or nonfatal stroke (HR could not be estimated). The incidence of hypercalcemia and hyperphosphatemia was similar between groups. None of the participants underwent parathyroidectomy.

Conclusions: In adults treated with hemodialysis and who had vitamin D insufficiency, calcifediol supplementation for 24 months had inconclusive effects on mortality and cardiovascular outcomes.

Trial registration number: NCT01457001.

Keywords: Calcifediol; ESKD; Hemodialysis; Mortality; Vitamin D.

PubMed Disclaimer

References

    1. LaClair RE, Hellman RN, Karp SL et al (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45(6):1026–1033 - DOI
    1. Barreto DV, Barreto FC, Liabeuf S et al (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4(6):1128–1135 - DOI
    1. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840–853 - DOI
    1. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34(3):368–375 - DOI
    1. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD (2011) Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 6(1):50–62 - DOI

Publication types

Associated data

LinkOut - more resources